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Protein kinases have been a rich source of targets for drug discovery, 
with more than 25 therapeutics approved by the US Food and Drug 
Administration (FDA) and hundreds more in clinical evaluation1–3. 
Most academic and industrial research remains focused on only a 
small fraction of the kinome for which evidence of therapeutic utility 
already exists4. This has led to a drug-development pipeline with much 
overlap between pharmaceutical companies and many redundant clin-
ical studies5. To catalyze research on kinases that have received scant 
attention to date4, GlaxoSmithKline defined PKIS, a set of 367 kinase 
inhibitors that were previously published individually6.
Herein we provide a comprehensive characterization of PKIS com-
pounds. We used target-based assays to determine inhibitor selectivity 
and to identify chemical starting points for previously untargeted 
kinases. To evaluate off-target activity outside the kinase family, we 
collected screening data against 24 G protein–coupled receptors 
(GPCRs), revealing frequent cross-reactivity of some kinase scaf-
folds with this diverse target family. We also found cytotoxic and 
cytostatic compounds in a screen of the NCI-60 cancer cell line col-
lection, identified potential angiogenesis inhibitors in a high-content 
tube-formation screen and generated a selective inhibitor of the LOK 
and SLK kinases through structure-based modification of an inhibitor 
of the related kinase TIE2.
RESULTS
Defining the set
GlaxoSmithKline and its legacy companies have published the struc-
ture and activity of >3,000 small-molecule inhibitors that cover a 
range of kinase targets and chemotypes. We selected compounds from 
this pool to form an open-source set. As an initial filter, we applied 
the practical requirement of a material supply of >5 mg of sample. 
Each compound was assigned to a specific chemotype, and in the 
case of heavily populated chemotypes, which have often been the 
focus of extensive efforts in analog synthesis, we conducted addi-
tional filtering to reduce the number of representatives to <40 while 
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maximizing the diversity of activity profiles 
across kinases. Within a given chemotype, 
we sought to include compounds having 
a range of activities at the primary target 
and across other kinases. Compounds with 
less than 98% purity as measured by liquid 
chromatography–mass spectrometry (LC-MS) 
were excluded. At the end of the triage 
process, 31 chemotypes containing a total 
of 367 compounds from programs origi-
nally targeting 24 different kinases remained 
(chemical structures, identifying codes and 
literature references for each compound in 
the PKIS are provided in Supplementary 
Table 1, Supplementary Fig. 1 and 
Supplementary Data).
The majority of the PKIS compounds 
had physicochemical properties within the 
bounds of the commonly recognized drug-like space. Two-thirds of 
the set had molecular weight (MW) <500 Da and a log of the partition 
coefficient between octanol and water (clogP) <5. The set included 
some high-MW and high-clogP compounds, many of which were 
designed to target a conserved lipophilic ‘back pocket’ region. Known 
collectively as type II or DFG-out inhibitors because they induce 
a conformational change involving a loop containing conserved 
Asp-Phe-Gly (DFG) residues7, these inhibitors have proven useful for 
drug discovery despite the potential liabilities associated with their 
physicochemical properties.
In vitro characterization of the PKIS
Each PKIS member was previously published with a limited set of activ-
ity data. To improve annotation of the set as a whole, we screened the 
PKIS against a panel of 224 recombinant kinases, which included 196 
unique members of the human protein kinome, 21 mutants associated 
with disease phenotypes and 5 lipid kinases (Fig. 1a, Supplementary 
Table 2 and Supplementary Data). The Nanosyn enzyme assay 
panel employed microfluidics capillary electrophoresis technology 
to measure the change in electrophoretic mobility of the substrate—
usually a fluorescence-labeled peptide or lipid—upon phosphor-
ylation. The simultaneous determination of substrate and product 
was employed to increase assay precision. The panel represented 
approximately 40% of the human protein kinome and was biased toward 
previously targeted kinases and close relatives. The data were collected 
as single measurements at two inhibitor concentrations (100 nM 
and 1 M), with the concentration of ATP at the apparent Km of 
ATP of the particular kinase being profiled (Fig. 1b,c). Comparison 
of duplicate measurements for two compounds indicated that  
the data were concordant, affirming the utility of this screening 
approach (Supplementary Fig. 2).
The PKIS was further screened against a set of 68 kinases by  
differential scanning fluorimetry (DSF), measuring the increase in 
melting temperature ( Tm) of a kinase when exposed to a small-mol-
ecule inhibitor at 10 M (ref. 8) (Fig. 1e and Supplementary Data). 
For the 32 kinases in common between the two panels, the correlations 
of assay data were r = 0.45 (Nanosyn panel screening at 0.1 M) and  
r = 0.63 (Nanosyn panel screening at 1 M) despite the difference in 
inhibitor concentration between assays. The degree of correlation 
between these two assay types might also be affected by differences 
in phosphorylation or activation state of the kinase. Nonetheless, the 
pattern of selective compounds and promiscuous chemotypes was 
preserved between the two panels (Fig. 1e).
Kinase screening results
Several broad trends were revealed by the screening data (Fig. 1). 
Visualization of the data set showed that the original kinase targets 
of each chemotype were often associated with the most significant 
cluster and that the tyrosine kinase (TK), CMGC and STE 
subfamilies were inhibited by a larger percentage of the inhibitors 
than were other subfamilies (Fig. 1d,  Supplementary Table 3 and 
Supplementary Fig. 3). Although previ-ous reports have associated 
increased inhibitor MW with promiscuity9, our data set did not 
show an evident relationship between MW and the number of 
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Figure 1 PKIS–kinase screening. 
(a) Phylogenetic tree of kinases screened 
against the PKIS by Caliper assay at Nanosyn, 
Inc. (blue circles) and by DSF (yellow circles).
(b,c) Heat maps of Caliper assay screening
at 0.1 M (b) and 1 M (c) compound.
(d) Annotated heat map of Caliper assay 
screening at 0.1 M compound (Supplementary 
Table 1). (e) Heat map of DSF screening
of the PKIS against 68 kinases. Tm shifts  
of >4 °C are shown in yellow. The green  
arrow (a–e) marks the start and direction  
of the circular sorting order applied to the 
kinases sorted by circular distance around  
the phylogenetic tree and compounds sorted 
by chemotype. Inhibition from 0% to 100%  
is shown as a gradient of blue to yellow.
or 1.0 M. Indeed, the most promiscuous 
compounds were the relatively small pan-TK 
inhibitors GW559768X and GW440139A 
(Fig. 2a). Ten compounds inhibited more than 
20 kinases by >50% at 100 nM. The original 
targets for these compounds were not local-
ized in a single branch of the kinome but 
span the TK (GW559768X, targeting RET; 
GSK1173862A and GSK1326255A, targeting 
IGF-1R), the CMGC (GW779439X, targeting 
CDK) and the AGC (GSK1007102B, target-
ing Akt) subfamilies. Notably, the compounds 
showed patterns of activity that were distinct 
across the kinome, although each compound 
was associated with clusters of activity in the particular subfamily  
of its original kinase target (Supplementary Fig. 4). For comparison, 
the well-characterized nonspecific kinase inhibitor staurosporine, 
included as a control compound at 80 nM, inhibited 153 of the 224 
kinases by >50%.
The profiling data also identified several compounds as highly 
selective across the kinase panel, including some that had been pre-
viously reported as chemical probes on the basis of fewer assays. For 
example, SB-686709-A and SB-698596-AC were originally reported 
as selective inhibitors of glycogen synthase kinase-3  (GSK3 ) in a 
panel of 25 kinase assays10; after extensive profiling these compounds 
were confirmed as highly selective inhibitors of GSK3  and GSK3  
(Supplementary Fig. 5). The data also verified the high selectivity of 
GW632580X for colony-stimulating factor-1 receptor (cFMS)11 and 
SB-590885-AAD for BRAF12 (Supplementary Table 4).
Only 16 compounds had a maximum inhibition of <20% at 1.0 M 
across the assay panel. These structurally related inactive compounds 
can be useful in several contexts, such as in the interpretation of cellular 
profiling data and correlation with protein structural information13.
The Nanosyn panel data set allowed an assessment of the breadth 
of kinome activity coverage by the PKIS. Of the 224 kinase assays 
in the assay panel, 156 kinases were inhibited >50% by at least one 
compound at 100 nM (Fig. 2b), and 18 kinases were inhibited <50% 
at 1 M by any compound.
Plotting the data of the unique protein kinases screened in the 
Nanosyn (excluding disease-related mutants) and DSF panels on a 
kinase phylogenetic tree showed extensive coverage with only a few 
small clusters of noninhibited kinases (Supplementary Fig. 6). A 
subset of 24 kinases were inhibited by single compounds with selectiv-
ity over other kinases (i.e., 24 kinases were inhibited by compounds 
having only a single kinase activity >50% at 100 nM).
This breadth of kinome coverage was observed despite the 
modest number of compounds in the set, the overrepresentation of 
inhibitors designed to target the TK and CMGC families and the 
composition of the assay panel that favors ‘targeted’ kinases. The 
most frequently inhibited kinases, as measured by the number 
of compounds with >50% inhibition at 1 M, were the TKs LYN, 
PDGFR , PDGFR  and KDR (VEGFR2). From the more stringent 
data at 100 nM compound concentration, there were three CMGC 
kinases (GSK3 , GSK3  and p38 ) and six TKs (EGFR, KDR, KIT, 
PDGFR , PDGFR  and RET) that were inhibited by more than 20 
compounds (Fig. 2c).
Examples of analysis within chemotypes
A compound set composed of multiple compounds within each 
chemotype aids greatly in defining structure–activity relationships 
(SARs). Owing to space constraints it is not possible to discuss here 
all SARs that can be deduced from this large data set; however, we 
provide examples that will help to illustrate the value of this approach, 
both in terms of target-specific information and broader ‘survey’ 
analysis (Supplementary Figs. 7 and 8).
Example chemical probe starting points
The kinase inhibition data confirmed the utility of PKIS in the 
identification of chemical starting points for probes of historically 
understudied kinases. As an illustration of this utility, we found 89 
kinases (73 wild type and 16 mutant) that were inhibited by >40% by 
at least one compound at 100 nM, where that compound inhibits no 
more than 10% of tested kinases by 50% at 1.0 M and the kinase is in 
the top 5 hits for that compound (Supplementary Table 5). More than 
50% of these kinases are historically understudied targets for which 












































Number of kinases inhibited
>50% by each compound
























>50% inhibition at 0.1 M





























Figure 2 Analysis of kinase screening data. 
(a) Number of kinases inhibited by each
compound at >50%, at 0.1 M compound.
The compounds and chemotypes are sorted
as in Figure 1. Some of the most promiscuous
inhibitors are depicted; selectivity profiles
for these compounds are available in
Supplementary Figure 3. (b) Protein kinome
phylogenetic tree of PKIS original kinase
targets and kinases with >50% inhibition
at 0.1 M by at least one compound.
(c) Number of compounds that inhibit
each kinase at >50%, at 0.1 M compound.
The kinases are sorted as in Figure 1d.
(d) Selectivity profiles for example starting
points toward chemical probes identified 
in the screening.
Using the heat maps to compare the original 
target of each compound with the full range 
of kinase inhibition revealed numerous start-
ing points for chemical probe development 
against previously untargeted kinases. We
plotted a few example clusters (Figs. 1d, 2d
and Supplementary Table 6). Examples of notable inhibition pro-
files were found in SB-739245-AC, which maintained its previously
reported potency against GSK3  and GSK3  while also inhibiting 
cyclin-dependent kinase 6 (CDK6) and cyclin A and mitogen- 
activated protein kinase–interacting serine/threonine kinase 1 
(MNK1); and GSK204925, from a series originally targeting polo-
like kinase 1 (PLK1), which inhibited brain-specific serine/threonine 
kinases 1 (BRSK1) and BRSK2 and lymphocyte-oriented kinase (LOK, 
also known as STK10). The amino acid sequence of the two BRSK 
isozymes is highly conserved in the ATP binding site, and inhibitors 
showed no selectivity across the set (r = 0.95 at 0.1 M; r = 0.96 at 
1.0 M, Supplementary Fig. 9). SB-633825, synthesized as a TIE2 
inhibitor, showed potent inhibition of LOK and BRK (Fig. 2d) with 
a relatively clean inhibition profile. We follow up this observation 
below as an example of the development of a specific chemical probe 
for LOK and SLK.
Even weak hits showing inhibition only at higher concentrations 
may be useful starting points for further inhibitor optimization; 20% 
inhibition at 1 M projects to a half-maximal inhibitory concentra-
tion (IC50) < 10 M (Supplementary Table 7). We also observed some 
unexpected cross-reactivities; GSK317314A, a PLK1 inhibitor, also 
strongly inhibited NIMA-related kinase 9 (NEK9) at 0.1 M (PLK1 
98%, NEK9 77%) (Supplementary Table 8).
An example chemical starting point identified by DSF is SB-742864, 
which showed Tm = 7.1 °C for adapter protein 2–associated 
kinase 1 (AAK1). This compound had Tm ≥ 4 °C with only two 
other kinases in the panel (STK16 and CDK2, with Tm = 4.9 °C 
and 4.4 °C, respectively). Nanosyn kinase inhibition data showed 
that all kinases in that panel were inhibited <20% at 1 M (except 
ABL T315I, at 31% inhibition). The affinity of SB-742864 for AAK1 
was confirmed in a split luciferase assay system14, where it inhibited 
AAK1 activity with IC50 = 220 nM (data not shown). Several other 
members of the 3-aminoindazole series showed AAK1 Tm  4 °C 
while maintaining selectivity over the other kinases in the Nanosyn 
panel, increasing confidence in this series as a source of AAK1 inhibi-
tors for optimization.
GPCR profiling
ATP-competitive kinase inhibitors can have cross-reactivity with 
targets beyond the kinome—for example, by interacting with the 
aminergic GPCRs15. Such cross-reactivity may lead to unexpected 
phenotypic responses but may also be used for the design of 
inhibitors outside the kinase family16,17. To provide additional 
target-based activity characterization, we profiled the PKIS against 
24 GPCRs in calcium mobilization assays (Supplementary Table 9 
and Supplementary Data).
No PKIS compound had any measurable agonist activity against 
these GPCRs. However, several compounds showed antagonist  
activity (Fig. 3a). We analyzed the GPCR screening results using 
ADDAGRA software, which represented the 24 GPCRs as nodes 
linked by edges18 (Fig. 3b). The presence of an edge connecting two 
receptor nodes indicates the similarity of the entire screening pro-
file for all 367 compounds against the two (connected) GPCRs. The 
GPCRs P2Y11, V1B and, in particular, OT were clear outliers, whereas 
others (for example, V1A, M3D and P2Y2) clustered together.
Some PKIS compounds (such as GW406108X) were character-
ized by complex and promiscuous GPCR activity profiles (Fig. 3c),  
whereas others showed highly selective profiles (Fig. 4). The con-
certed analysis of the kinase and GPCR screening data allowed us 
to select several compounds with unique profiles for confirmatory 
assays. For example, GSK238583A was found to be a potent epidermal 
growth factor receptor-4 (ERBB4) inhibitor (IC50 = 6.7 nM) but was 
inactive against any of the GPCRs. Another compound, GW682841X, 
had limited kinase inhibition potency but appeared to be a selective 
antagonist at P2Y receptors on the basis of the primary screening data. 
GW682841X was confirmed to have antagonistic activity at P2Y1, 
P2Y2 and P2Y11 in secondary screening assays. GW682841X reduced 
agonist efficacy in a concentration-dependent manner, suggesting 
that its interaction is based on a noncompetitive mechanism or is 
competitive because of hemi-equilibrium. The GW682841X antago-
nist activity was different at P2Y subtypes, as it reduced potency of 
ADP at the P2Y1 receptor and ATP at the P2Y2 receptor but enhanced 
ATP potency at the P2Y11 receptor. These results were consistent with 
an allosteric interaction with P2Y endogenous agonists. By contrast, 
its antagonist activity at P2Y4 and P2Y6 receptors was much weaker 
(data not shown).
Profiling in the NCI-60 cancer cell line panel
The NCI-60 panel of human cancer cell lines is a well-characterized 
platform for the cellular screening of potential anticancer agents19,20. 
A number of powerful online tools are available to enable data analysis, 
including COMPARE (https://dtp.nci.nih.gov/databases_tools/compare. 
htm) and CellMiner (http://discover.nci.nih.gov/cellminer/)21.
The effect on cell growth of each PKIS compound was evalu-
ated in duplicate at five concentrations ranging from 2.5 nM to 
















































































Figure 3 PKIS–GPCR antagonist assay 
screening at 8 M of each compound.  
(a) Heat map of responses with 24 clustered
columns of GPCRs and 367 clustered PKIS
compounds. Yellow indicates no effect; red
indicates maximum potentiation effect; green
indicates antagonist effect (complete inhibition
of the effect of a control agonist). (b) ADDAGRA
representation of GPCR antagonist profiles.
(c) GPCR antagonist profile (1) and kinase
inhibition profile (2) for the promiscuous 
compound GW406108X.
(Supplementary Data). Three data points were interpolated from 
the response data for each compound in each cell line: GI50, the 
concentration at which cell growth was inhibited by 50% over the 
48-h time course of the assay; TGI, the concentration resulting in
total cell growth inhibition; and LC50, the concentration at which
50% of the cells were killed.
The heat map of hierarchically clustered GI50 values showed a 
range of sensitivity and resistance for the PKIS compounds across 
the cell lines (Fig. 5a). The activity pattern across the panel for a given 
compound can provide insight into function, and the COMPARE 
algorithm draws on such patterns in the NCI-60 data to associate 
compounds with common mechanisms of action. Activity patterns 
of PKIS compounds that inhibit specific 
kinases in vitro are labeled on the heat map. 
In addition, a network diagram of pairwise 
matrix COMPARE correlation values ( 0.7) 
for 208 of 367 PKIS compounds that have 
a range of –log GI50 (also known as pGI50) 
values >1.0 allows for a visual representation 
of agents with related effects on the NCI-60 cell lines (Fig. 5b). For 
example, the GI50 cell-line pattern profiles of dual inhibitors of epi-
dermal growth factor receptor (EGFR) and ERBB2 transmembrane 
protein kinases were, in general, highly correlated when we used the 
COMPARE algorithm, and one such compound (GW583373A) had 
a pattern highly similar to that of the FDA-approved BRAF inhibitor 
vemurafenib lapatinib, the FDA-approved selective dual inhibitor of 
EGFR and ERBB2 (r = 0.91). In another example, the activity patterns 
of the BRAF inhibitors also formed a tight cluster in the network dia-
gram with the PKIS compound SB-590885 showing a high COMPARE 
correlation value (r = 0.91) with the structurally unrelated FDA-
approved BRAF inhibitor vemurafenib.
GSK238583A–ERBB4
GSK238583A





































































































Figure 4 Concentration response curves for compounds GSK238583A, GSK711701A and GW682841X, selected on the basis of their GPCR antagonist 



























































Figure 5 Screening against the NCI-60 panel. 
(a) Hierarchical clustering (unweighted pair
group method with arithmetic mean) heat 
map representation of the pGI50 NCI-60 data 
for PKIS compounds. (b) Network diagram of 
pairwise matrix COMPARE correlations for the 
208 out of 367 PKIS compounds that have 
pGI50 values greater than 1.0. An edge connects 
two compounds if the pairwise correlation is 
greater than 0.70. 
The concordance of the NCI-60 cell-line response patterns for 
several compounds with their known target-based profiles increased 
our confidence in the data set. However, the agents with cellular 
response patterns that are distinct from those of clinically approved, 
highly selective kinase inhibitors may be of more interest. One such 
compound is GW768505A. The GI50 values for this compound were 
in the approximate range of 300 nM to 3.0 M for all cell lines except 
for the colon cancer-derived KM12 line, where GW768505A had 
GI50 = 6.3 nM. The kinase target profile of GW768505A, a compound 
originally developed to target KDR and TIE2 (ref. 22), showed potent 
inhibition (71–88% inhibition at 100 nM) of the tropomysin-related 
kinases TRKA, TRKB and TRKC. The KM12 cell line is associated with 
overexpression of TRKA and is sensitive to TRKA inhibition23. On the 
matrix COMPARE network diagram, the GI50 pattern for GW768505A 
was highly correlated (r > 0.7) with the patterns of two oxindole TRKA 
inhibitors (GW278681X and GW441756X). To demonstrate TRKA 
activity, we showed that both GW768505A and GW441756X inhibit 
TRKA autophosphorylation in KM12 cells (Supplementary Fig. 10), 
with GW441756X acting faster. GW768505A was significantly more 
potent against the human colon cancer cell line KM12 than was 
GW441756X, raising the possibility that an additional cellular target 
of GW768505A contributes to its potent GI50.
A second example resulted from running a standard COMPARE 
for the GI50 pattern derived from the KDR- and TIE2-targeting 
agent GW683134A24 against the NCI-60 compound collection 
data set. This analysis revealed a high correlation (r = 0.81) with 
the response pattern for the structurally unrelated multitargeted 
kinase inhibitor ponatinib.
Optimization of a dual chemical probe for LOK and SLK
SB-633825 profiled as a potent inhibitor of LOK in addition to its 
original target TIE2 and served as a starting point for generation of a 
selective inhibitor of the LOK and SLK kinases.
Twenty derivatives of SB-633825 were tested for activity against 
LOK, p38  and TIE2 (Fig. 6a). Two compounds retained inhibi-
tion of LOK while losing all activity against TIE2. GSK3037619A 
and SB-440719 showed high selectivity in the Nanosyn kinase 
assay panel (which had been expanded to 255 kinases assays com-
pared with the original panel used for PKIS screening) with LOK 
and SLK as the top targets (Supplementary Table 10). LOK and 
SLK are close homologs and have a conserved ATP binding site 
(SLK was not in the earlier Nanosyn panel of 224 kinases). We 
co-crystallized SB-633825 with LOK and were able to obtain  
two X-ray structures in different crystal forms (Supplementary  
Table 11). The structures confirmed the ATP-competitive binding 
mode of SB-633825 and showed that in one crystal form, LOK was 
in the inactive ‘DFG-out’ conformation, and in the other LOK was 
in the active ‘DFG-in’ conformation (Fig. 6b). With SB-440719 it 
was possible to obtain a high-resolution (1.75-Å) co-crystal structure 
with SLK (Fig. 6c). The structure confirmed the binding mode of the 
inhibitor and revealed two notable features: (i) the glycine-rich loop 
(P-loop) formed an unusual conformation to allow Phe45 to bind the 
imidazole ring of the inhibitor and (ii) the activation loop packed 
against the inhibitor and the P-loop to reinforce this binding (Fig. 6d).  
The sequence of the glycine-rich loop (GELGDGAFGKVY) is well 
conserved only in the neurotrophic receptor tyrosine kinases 1–3, 
which were not inhibited by SB-633825.
To validate the utility of the more potent SLK-LOK inhibitor, 
GSK3037619A, we first measured direct binding to LOK and SLK by 
biolayer interferometry. GSK3037619A bound to LOK and SLK with 
Kd values of 63 nM and 199 nM, respectively (Supplementary Fig. 11). 
These values were consistent with the enzymatic assay data. We also 
assessed the ability of GSK3037619A to inhibit LOK and SLK in cells. 
As LOK may be the dominant ezrin-radixin-moesin (ERM)-phospho-
rylating kinase in lymphocytes25–27, we assessed ERM phosphorylation 
in Jurkat T cells. Application of GSK3037619A had a clear effect on ERM 
phosphorylation in repeated experiments (Supplementary Fig. 11e).
High-content screen for regulators of angiogenesis
We also screened the PKIS for compounds targeting angiogenesis, 
as such targeting is a therapeutic strategy for the treatment of cancer 
and cardiovascular diseases28.
To characterize the activity of PKIS compounds on angiogenesis, a 
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Figure 6 Additional characterization of kinase chemical probe starting points. (a) Identification of selective inhibitors of LOK with increased selectivity. 
Chemical structures of all compounds are available in the Supplementary Data. (b) Crystal structures of SB-633825 with LOK in inactive DFG-out state 
(left, PDB 4USD) and active DFG-in state (right, PDB 4USE). Green, N-terminal lobe; blue, C lobe; red, DFG motif. (c,d) Crystal structure of  
SB-440719 with SLK (PDB 4USE) (c) and showing the involvement of the activation loop (red spheres) in binding the inhibitor (yellow spheres) (d).
assay29 (Supplementary Data). This assay captured many cellular 
processes essential to the growing vascular network, such as establish-
ment of new connections, branching and tubulogenesis.
The antiangiogenic activity of the PKIS compounds was correlated 
with the kinase inhibition data (Fig. 7a and Supplementary Fig. 12). 
Overall, 65 compounds from the PKIS significantly inhibited the 
formation of endothelial tubules (B score 1.5, 2× median absolute 
deviation (MAD)). Most of these compounds target multiple receptor 
tyrosine kinases such as PDGFRs, c-KIT, RET and VEGFRs, that are 
known to be involved in the initiation of angiogenesis. Antiangiogenic 
tyrosine kinase inhibitors such as sunitinib and sorafenib have been 
previously employed as a therapeutic strategy against cancer30,31.
The most notable target of angiogenesis inhibitors was the vascu-
lar endothelial growth factor (VEGF) signaling pathway (Fig. 7b). 
Among VEGF receptors, only KDR is exclusively expressed on the 
endothelium. Its expression level is very low in normal vasculature32, 
but it becomes highly activated during the growth of new blood vessels 
in tumors. Notably, we have identified GW786460X (originally target-
ing transforming growth factor-  receptor 1 (TGF- R1), which was 
not in the kinase screening panel) as a potent inhibitor of KDR that is 
capable of substantially reducing tubule formation (Fig. 7c). It is less 
aggressive on the capillary-like network morphology compared to the 
pan-TK inhibitors such as GW795493X (originally targeting TIE2 and 
KDR). The use of selective KDR inhibitors may avoid undesirable side 
effects that result when using pan-TK inhibitors such as sunitinib33. 
Other PKIS compounds targeting kinases such as AKT, GSK3, p38, 
RAF and JNK also reduced endothelial tube formation. Compounds 
with cytostatic or antiproliferative properties, such as inhibitors of 
PLK or of EGFR and ERBB2, did not exhibit an antiangiogenic effect, 
an observation that may be due to the assay’s duration of <12 h.
DISCUSSION
Several large-scale kinase screens have been described previously1,9,34–41. 
Although they have increased understanding of many aspects  
of kinase pharmacology, their impact in drug discovery has been  
 
limited because they used undisclosed, unavailable and/or proprietary 
compounds or because the compounds studied were singletons— 
individual, structurally unrelated compounds that were typically 
clinical candidates or ‘tool compounds’. In cases where structurally 
related compounds were included42,43, the insight into the molecular 
features for kinase inhibition enabled improved inhibitor design.
PKIS was designed to facilitate functional characterization of pre-
viously untargeted kinases. We provide free access to the physical 
compounds along with all of the chemical structures as an experiment 
in precompetitive compound sharing and open-access chemical biol-
ogy (details are given in Online Methods). As compounds of interest 
are identified and testable hypotheses formed, individual solutions 
in larger quantity or solid samples of compounds may be made 
available to investigators for more detailed studies. For compounds 
whose supply is limited, procedures for their preparation are publicly 
available in the scientific literature. Compound transfer entails 
minimal legal requirements and no claims to intellectual property of 
resulting findings. However, data derived from use of the set must be 
placed directly into the public domain.
The uptake of PKIS in the scientific community has been encour-
aging. To date the set has been dispensed to over 250 collaborators, 
resulting in a large and growing body of data deposited at ChEMBL 
(https://www.ebi.ac.uk/chembl/). Applications have covered diverse 
biology, including characterizing the set for intrinsic luciferase inhi-
bition activity to aid interpretation of phenotypic screens employing 
luciferase reporter assays44; profiling the set in an advanced model of 
the rare brain cancer ependymoma45; using PKIS in structural guided 
design of dual kinase and bromodomain inhibitors46; and progression 
through an in situ Western screen for inhibitors of ATM kinase47. 
PKIS was designed to capitalize on the chemical connectivity of ATP-
competitive inhibitors that often show cross-reactivity across multiple 
kinases. Although medicinal chemists have developed strategies to 
address kinase selectivity, PKIS takes advantage of the potential for 
off target kinase activity to use the same chemotypes to explore the 
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Figure 7 Phenotypic screen for angiogenic 
activity of PKIS compounds. (a) Kinase inhibition 
heat map (as in Fig. 1) with compounds sorted 
according to angiogenic activity (B score of total 
tubule length) obtained by an endothelial tube-
formation assay on primary human umbilical vein 
endothelial cells. Red arrows mark the cutoff for 
angiogenesis inhibitors or enhancers (2× MAD). 
Kinases involved in angiogenesis are indicated 
on the x axis. (b) Most PKIS compounds showing 
>50% inhibition of KDR exhibited a significant
reduction of total tubule length (angiogenesis),
B score 1.5 (2× MAD). Orange circles represent
compounds originally targeting TIE2 and
KDR. (c) Left, kinase inhibition profile of
GW786460X (original target TGF- R1) showing
>50% inhibition of KDR at 0.1 M (green)
and fluorescence images of endothelial
capillary-like network formation produced with
GW786460X (10 M) versus DMSO (vehicle);
right, kinase inhibition profile of GW795493X
(original targets: TIE2 and KDR) showing
inhibition of multiple receptor tyrosine kinases,
including KDR, and fluorescence images
showing endothelial capillary-like network
structure produced with GW795493X (10 M)
versus vehicle.
points for hitherto untargeted kinases (such as LOK, BRSK1/2, 
MKNK1 and AAK1) have been identified from the PKIS with  
modest affinity values and selectivity profiles.
In addition to the identification of chemical starting points for 
new kinases, the kinase activity map across a panel of hundreds of 
kinases can inform cellular screening efforts. Although biochemi-
cal assessments of kinase inhibitor interactions generally correlate 
with cellular efficacy48, the extrapolation of our in vitro results to the 
interpretation of cellular efficacy should proceed with a few caveats 
in mind. First, the Nanosyn kinase screening was conducted in the 
presence of ATP near the equilibrium constant for binding (Km) of 
the cofactor to the kinase. As such, the concentration of ATP varied 
across the panel by over two orders of magnitude. Cellular potency 
of ATP-competitive kinase inhibitors is determined not only by the 
intrinsic affinity of the inhibitor for the kinase but also by the Km 
of ATP and the cellular concentration of ATP48. Thus, the apparent 
potency and the rank order of kinase inhibition may differ in the cel-
lular context. Second, many kinases in the panel are represented by 
constructs whose interactions with a compound could differ from that 
of endogenous enzyme, particularly in a cellular environment where 
protein scaffolding partners may be present. Third, although half of 
the human protein kinome is represented by the Nanosyn and DSF 
screening panels, there is likely additional compound activity with 
untested kinases or other targets.
The cellular activity of PKIS compounds was evaluated in the NCI-
60 panel and in a model of angiogenesis. The results demonstrate 
the applicability of the set to phenotypic screening. The compounds 
showed a wide variety of activity profiles, potent cellular activity, and 
minimal nonspecific cytotoxicity. These data are expected to comple-
ment existing activity annotation and to inform future cellular screens 
involving PKIS.
Several recent observations suggest interactions of ATP-competi-
tive kinase inhibitors with non-kinase targets15. ATP itself has been 
used to make an affinity capture reagent to identify more than 2,000 
proteins that bind purine nucleotides as substrates or cofactors49. 
The results of screening PKIS in a panel of GPCR assays underscore 
the value of broad activity profiling to identify off target activity that 
might account for aberrant cellular activity or to increase understand-
ing of kinase inhibitor polypharmacology.
Despite encouraging indications of the utility of the PKIS,  
the screening results point to opportunities to improve the set. If 
the figures of kinome coverage were extrapolated from the assay 
panels, the PKIS would provide inhibitor scaffolds for 90% of the 
kinome, or 467 kinases. However, many atypical kinase targets were 
not included in the screening panel, and the overall hit rate may 
ultimately be lower when these are included. It should be possible 
to expand coverage of the kinome through inclusion of additional 
compounds, whether from new chemotypes or expansion of those 
already present in the set. In addition, as redundant inhibition pro-
files or liability target activity are identified, compounds may be 
culled from the set.
In summary, we have presented PKIS, an open resource to stimulate 
research into the historically understudied kinome. It is hoped that 
the compounds and characterization data will help to illuminate the 
kinome further and identify new therapeutic targeting opportunities 
for pioneer medicines.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. PDB: The crystal structures of LOK (STK10) and 
SLK with inhibitors have been deposited in the Protein Data Bank 
under accession codes 4USD, 4USE and 4USF.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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compound was used to measure a dose-response curve of association and 
dissocation. Kd values were calculated in GraphPad Prism using the one-site 
specific binding model.
GPCR screening. Calcium mobilization assays were carried out with cells sta-
bly expressing cloned human receptors essentially as described previously50–52, 
and complete protocol details are available online (https://pdspdb.unc.edu/
pdspWeb/?site=functional). In brief, cells were seeded in poly-l-lysine– 
coated 384-well black clear-bottom cell-culture plates using DMEM supple-
mented with 1% dialyzed FBS in a total of 40 l per well and at a density of 
15,000 cells per well and left overnight. On the day of assay, medium was 
removed and cells were loaded (20 l/well) with Fluo-4 Direct dye (Invitrogen) 
prepared with assay buffer (1× HBSS, 20 mM HEPES, 2.5 mM probenecid, 
pH 7.40) for 1 h at 37 °C. A fluorescence imaging plate reader (FLIPRTETRA, 
Molecular Dynamics) was programmed to read baseline fluorescence for 10 s 
(1 read per second), then to add 10 l of drug per well to assess agonist activity. 
The FLIPR was programmed to wash tips then add a reference agonist at a 
final concentration of EC80 (the concentration to elicit 80% of the maximum 
reference agonist, predetermined before antagonist activity assay) to assess 
potential antagonist activity 10 min later. The baseline for antagonist activity 
was the average fluorescence of 10 readings before addition of EC80 refer-
ence agonist with the fluorescence in each well corrected and normalized to 
corresponding baselines. The maximum signals (fold of baseline) during 60 s 
after drug addition were then exported. Agonist activity in initial screening 
assays was determined at a final concentration of 10 M (quadruplicate deter-
minations) and normalized with the corresponding reference agonist activity 
as 100% and basal as 0%. Antagonist activity in screening assays was measured 
at a final concentration of 8 M and normalized with basal representing 100% 
inhibition and the agonist activity at EC80 concentration as 0% inhibition. For 
Schild plot analysis, agonist concentration-responses (16 points in triplicate) 
were measured in the absence and presence of increasing concentrations of 
test compounds. Results were analyzed using GraphPad Prism 5.0.
NCI-60 panel screening. The set was screened across the NCI-60 panel at the 
National Cancer Institute using previously described methodology, protocols 
and cell-line verification53.
Cellular assays. The KM12 cell line was obtained from the National Cancer 
Institute. The Jurkat cell line was obtained from A.P. Cribbs (Kennedy Institute 
of Rheumatology, Oxford University). All cell lines were regularly checked for 
mycoplasma contamination.
Anti-TRKA-pY496 and anti-TRKA antibodies were from Santa Cruz 
Biotechnology (#sc-7987 and #sc-118), anti–phospho-ERM antibody was from 
Pierce/Thermo Scientific (#MA5-14998) and anti-moesin was from Abcam 
(#ab52490) and anti-GAPDH (14C10) was from New England Biolabs (#2118S). 
All antibodies were validated for Western blots against the protein targets used 
by the antibody vendor. Antibodies were used at the following dilutions: sc-7987, 
1:200; sc-118, 1:200; MA5-14998, 1:1,000; ab52490, 1:10,000;  2118S, 1:1,000. 
The KM12 cells were cultured in RPMI 1640 media (Sigma, R0883) supple-
mented with 2 mM l-glutamine (Invitrogen, 35050) and 10% heat-inactivated 
FBS (Life Technologies, 10500-064). Twenty-four hours before treatment cells 
were seeded in 6-well plates (7.5 × 105 cells per well). KM12 cells were treated 
with GW768505A or GW441756X positive control at a concentration of 250 
nM for 2.5, 5.0, 15 or 30 min, at 37 °C and 5% CO2. DMSO was used as negative 
control. After treatment, cells were immediately washed and scraped using cold 
PBS containing 1% of PhosSTOP inhibitor cocktails (Roche, 04906845001), then 
collected by centrifugation at 2,500 r.p.m. at 4 °C for 3 min.
Jurkat cells were cultured in DMEM supplemented with 2 mM l-glutamine 
(Invitrogen, 35050) and 10% heat-inactivated FBS (Life Technologies, 10500-
064). Cells were counted and aliquoted in single 2-mL centrifuge tubes at a 
concentration of 2 × 106 cells per tube. Jukart cells were then treated with 
GSK3037619A, erlotinib or staurosporine at 1 M for 5 min at 37 °C and 5% 
CO2, in the presence or absence of 80 nM phosphatase inhibitor calyculin A 
(Cell Signaling, #9902). DMSO, plus or minus calyculin A, was used as nega-
tive control. After treatment, cells were immediately washed using cold PBS 
containing 1% of PhosSTOP inhibitor cocktails (Roche, 04906845001), then 
collected by centrifugation at 2,500 r.p.m. at 4 °C for 5 min.
ONLINE METHODS
Nanosyn caliper screening. Kinase activity was measured in vitro using 
an electrophoretic mobility shift assay. Kinase reactions were assembled in 
384-well plates in a total volume of 25 l. The reactions comprised: purified 
recombinant kinase enzyme, test compound, ATP (at apparent Km for each 
kinase, see Supplementary Data) FAM-labeled peptide substrates in a buffer 
composed of: 100 mM HEPES, pH 7.5; 10 mM MgCl2; 1 mM DTT; 0.1% BSA; 
0.01% Triton X-100, and 1% DMSO (from compound). Lipid kinases PI3K , 
PI3K  and PI3K  were assayed in reaction buffer comprising 50 mM HEPES, 
pH 7.5, 3 mM MgCl2, 1 mM DTT, 0.012% CHAPS, 40 mM NaCl, 0.01% 
BSA and using BODIPY-FL-labeled phosphatidylinositol 4,5-biphosphate 
(PIP2) as a substrate. PI4K  was assayed in reaction buffer comprising: 
50 mM HEPES, pH 7.5, 10 mM MgCl2, 0.1 mM DTT, 0.4% Triton X-100 and 
using BODIPY-FL-labeled phosphatidylinositol (PI) as a substrate. All reac-
tions were incubated at room temperature for indicated time (Supplementary 
Data) and quenched by addition of 45 L of termination buffer (100 mM 
HEPES, pH 7.5; 0.01% Triton X-100; 30 mM EDTA). Substrate and product 
peptides (or phospholipids) present in each sample were electrophoretically 
separated and detected using 12-channel LabChip3000 microfluidic capillary 
electrophoresis instrument (Caliper Life Sciences). The change in the 
relative fluorescence intensities of substrate and product peaks (reflecting 
enzyme activity) was measured. Capillary electrophoregrams were ana-
lyzed using HTS Well Analyzer software (Caliper Life Sciences). The kinase 
activity in each sample was determined as the product-to-sum ratio (PSR): 
P / (S + P), where P is the peak height of the product peptide and S is the 
peak height of the substrate peptide. Negative control samples (0% inhibition 
in the absence of inhibitor) and positive control samples (100% inhibition, 
in the presence of 20 mM EDTA) were assembled in replicates of four and 
were used to calculate percent inhibition values for each compound at each 












where PSRinh is the product-sum ratio in the presence of inhibitor, PSR0% is 
the average product-sum ration in the absence of inhibitor and PSR100% is 
the average product-sum ratio in 100%-inhibition control samples. Reference 
inhibitors (i.e., staurosporine, SB-202190, PP2) were tested in 8-point dose-
response format on each assay plate. The IC50 values of reference inhibitors 
were determined by fitting the inhibition curves by a four-parameter sigmoid 
dose-response model using XLfit 4 software (IDBS).
Differential scanning fluorimetry. The PKIS was screened against purified 
protein kinases according to previously reported procedures8.
Split luciferase assay. A coiled-coil enabled split-luciferase three-hydrid 
system assay was employed as previously reported14. Each test compound was 
screened in duplicate against AAK1 at seven different concentrations. The 
catalytic domain of AAK1 conjugated to the C-terminal fragment of luciferase 
(CFluc-kinase) was translated along with the N-terminal fragment of luciferase 
using a cell-free system (rabbit reticulocyte lysate) at 30 °C for 90 min. A 24- L 
aliquot of this lysate containing either 1 L of DMSO (for no-inhibitor control) 
or compound solution in DMSO was incubated for 30 min at room temperature 
and for 1 h in the presence of a kinase-specific probe. Luciferin assay reagent 
(80 L) was added to each solution and luminescence was immediately measured 
on a luminometer. Prior to initiating IC50 determinations, the test compounds 






The percentage inhibition was plotted against compound concentration, and 
the IC50 was determined for each compound using a seven-point curve.
Biolayer interferometry. Biotinylated LOK or SLK kinase domains were 
bound to tips of a FortéBio Octet RED instrument. A dilution series of each 
doi:10.1038/nbt.3374
Cells were lysed in RIPA buffer (Sigma-Aldrich, R0278) containing complete 
EDTA-free protease inhibitor cocktail (Roche, 11873580001) and PhosSTOP 
inhibitor cocktails. Protein concentration was determined using Pierce BCA 
Protein Assay Kit (Life Technologies, 23225) and 55 g of lysate was separated 
by SDS-PAGE. The molecular weight marker was from LI-COR (928-40000 
Odyssey Protein Molecular Weight Marker). Gels were transferred onto nitro-
cellulose membranes, blocked with 5% nonfat dry milk in 1× TBS containing 
0.05% Tween-20 (TBST) and then incubated with the appropriate primary 
antibody in 5% BSA in PBST. Membranes were washed in 1× TBST and incu-
bated for 1 h in the appropriate secondary antibody (goat anti-rabbit Alexa 
Fluor 680, #A21109) diluted 1:10,000 in 5% nonfat dry milk in PBST. The blots 
were washed and visualized using Odyssey CLx Infrared Imaging System.
High-content screening for modulators of angiogenesis. Primary human 
umbilical endothelial cells (HUVECs, pooled) were purchased from Lonza. Cells 
were maintained in endothelial cell medium (EGM-2, Lonza). Low-passage 
cells were used for the screen. Cells were seeded on top of Matrigel (an extract of 
basement membrane proteins, BD Bioscience), in 96-well plates and incubated 
with PKIS compounds at concentration of 10 M for 10 h at 37 °C and 5% CO2. 
The screen was performed in duplicate under rich vascular growth factor con-
ditions (full EGM-2 medium). Endothelial cells formed capillary-like vascular 
structures (tubules) in the presence of the Matrigel and vascular growth factors. 
The endothelial cellular tubules were fixed with 4% PFA and stained with Alexa 
Fluor 568 phalloidin (Invitrogen) to visualize the tubules. Next, the plates were 
imaged using a high-content microscopy system (Operetta, PerkinElmer). The 
16-bit images were processed, segmented and analyzed using fully automated 
Metamorph image analysis software (Molecular Devices) (Supplementary 
Fig. 12). Vehicle (DMSO) was used as negative control. Suramin was used as a 
positive control, which showed an effective inhibition of endothelial tube for-
mation in a dose-dependent manner (pilot validation assays). The total tubule 
length reading values were normalized according to the B-score method with 
the CellHTS2 package54. The B score is a normalization method to account 
for plate-to-plate variances that involves the residual values calculated from 
median polish and the median absolute deviation (MAD) of sample to account 
for data variability. The selection cutoff for inhibitor hits was set at 2× MAD, 
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Fig. 12c) and the Z factor was >0.3 in all plates. The data were compiled and 
analyzed using Spotfire and GraphPad packages.
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